Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Pozuelo De Alarcon – page 27

3 275 clinical trials in Pozuelo De Alarcon, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Pozuelo De Alarcon at a glance
3 275
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 275 trials in Pozuelo De Alarcon

Open in trial search

Study of TYRA-300 in Adults with Low Grade Upper Tract Urothelial Carcinoma to Assess Efficacy and Safety

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:TYRA-300-B01
  • Sponsor:Tyra Biosciences Inc.

Study of MK-1045 alone or with tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:MK-1045
  • Sponsor:Merck Sharp & Dohme LLC

Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Cemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemsidomide
  • Sponsor:C4 Therapeutics Inc.

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Delpacibart zotadirsen
  • Sponsor:Avidity Biosciences Inc.

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Pozuelo De Alarcon

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on multiple cancer types including bladder cancer, pancreatic adenocarcinoma, and non-small cell lung cancer. Studies evaluate novel combination therapies and targeted treatments.

  • Advanced solid tumors
  • Metastatic melanoma
  • Gastric cancer

Research includes immunotherapy approaches and antibody-drug conjugates for improved treatment outcomes.

02 Respiratory Medicine

Clinical investigations in respiratory conditions, including studies of RSV prevention in high-risk infants and novel treatments for uncontrolled asthma. Research focuses on innovative therapeutic approaches.

  • COVID-19 vaccine development
  • Respiratory infections
  • Inflammatory airway diseases

Studies evaluate both preventive measures and treatment interventions.

03 Neurological Disorders

Research targeting neurological conditions, with emphasis on Alzheimer's Disease and Multiple Sclerosis. Studies focus on disease-modifying therapies and novel treatment approaches.

  • Early-stage Alzheimer's treatment
  • Relapsing MS therapies
  • Neurodegeneration

Investigations aim to slow disease progression and improve patient outcomes.

04 Hematology

Studies in blood disorders including acute myeloid leukemia and immune thrombocytopenia. Research evaluates new therapeutic approaches and combination treatments.

  • Leukemia treatments
  • Myelodysplastic syndrome
  • Platelet disorders

Focus on improving survival rates and treatment efficacy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.